Gavi does not provide support for either the Ty21a or ViPS vaccines.
Read moreMessage Type: Typhoid Conjugate Vaccines
Typhoid Conjugate Vaccines 12
Expanding coverage of typhoid vaccines through routine immunization can reduce the need for antibiotics, slow further emergence of drug-resistant typhoid strains, and save lives.
Read moreTyphoid Conjugate Vaccines 11
A recent modeling analysis shows that TCV is likely cost-effective in countries with high typhoid incidence, high cost of typhoid treatment, and/or high death rates from typhoid.
Read moreTyphoid Conjugate Vaccines 10
Several other TCVs are in various stages of development.
Read moreTyphoid Conjugate Vaccines 8
Two other typhoid vaccines have been recommended by WHO since 2008, but because they do not give lasting immunity and cannot be given to children younger than two years old, ...
Read moreTyphoid Conjugate Vaccines 1
In 2018, WHO recommended TCV to be prioritized in countries with the highest burden of typhoid disease or a high burden of drug-resistant S. Typhi. TCVs are safe and effective ...
Read moreTyphoid Conjugate Vaccines 2
Results from large Phase 3 efficacy studies conducted in Bangladesh, Malawi, and Nepal show that TCV is safe and efficacious against typhoid in children 9 months and older in both ...
Read moreTyphoid Conjugate Vaccines 3
Based on studies, TCVs can be safely co-administered with yellow fever, measles-rubella, and meningococcal A vaccines. TCV has also been safely co-administered with polio and HPV vaccines.
Read moreTyphoid Conjugate Vaccines 4
TCVs are licensed for private use in several countries and is in various stages of planning for introduction into routine immunization programs in several countries.
Read moreTyphoid Conjugate Vaccines 5
A recent study found that Typbar TCV remains stable at 45°C, demonstrating that it can be used outside of the cold chain up to 7 days prior to administration. This ...
Read more
